Last reviewed · How we verify
Vitamin Mk 4 (MENATETRENONE)
Menatetrenone works by acting as a vitamin K analog to promote blood clotting.
Vitamin Mk 4, also known as menatetrenone, is a small molecule drug in the menatetrenone class that targets alpha-synuclein. It is currently used to treat hemorrhagic disease of the newborn due to vitamin K deficiency. The commercial status of Vitamin Mk 4 is unclear, as it is not known whether it is patented or generic, and it is not approved by the FDA for any indications other than its original use. The bioavailability of Vitamin Mk 4 is 23%, but its half-life is unknown. As a result, its use is limited to its original approved indication.
At a glance
| Generic name | MENATETRENONE |
|---|---|
| Drug class | menatetrenone |
| Target | Alpha-synuclein |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | discontinued |
Mechanism of action
Imagine your blood as a liquid that needs to be able to clot to stop bleeding when you get hurt. Vitamin K helps your body make the proteins that allow your blood to clot. Menatetrenone is a synthetic version of vitamin K that can help your body make these proteins and stop bleeding.
Approved indications
- Hemorrhagic disease of the newborn due to vitamin K deficiency
Common side effects
- Cerebral haemorrhage
- Cerebral infarction
- Hepatic function abnormal
- Disseminated intravascular coagulation
- Platelet count decreased
- Brain herniation
- Pneumonia
- Altered state of consciousness
- Embolic stroke
- Intraventricular haemorrhage
- Renal impairment
- Upper respiratory tract inflammation
Key clinical trials
- Bioavailability of Different Vitamin K Vitamers Studied Using 13C-labelled Vitamin K Vitamers (NA)
- Effect of Vitamin K2 Over Osteocalcin, Leptin, Cytokines, and Cardiovascular Risk in Young Adults With Overweight and Obesity (NA)
- Intervention Study of Drugs in Patients Osteopenia and Osteoporosis (NA)
- Vitamin K as Additive Treatment in Osteoporosis (PHASE2,PHASE3)
- The Effect of Vitamin K2 on Bone Turnover (PHASE4)
- Efficacy and Safety Study on Menatetrenone in the Treatment of Postmenopausal Osteoporosis Women (PHASE3)
- Evaluation of Factors II, VII, IX, X, and Proteins C and S, Following High-dose Vitamin K Supplementation (NA)
- The Effect of Vitamin K Supplementation on Glucose Metabolism (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |